drugset / Trial / NCT07217665
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
Phase 2
Not yet recruiting
146 enrolled
Adam Boxer
Alzheimer's Clinical Trials Consortium · collabAlzheimer's Therapeutic Research Institute · collabAxon Neuroscience SE · collabMassachusetts General Hospital · collabNational Institute on Aging (NIA) · collabUniversity of California, San Diego · collabUniversity of Southern California · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP. Regimen A will evaluate the safety and efficacy of a single study drug, AADvac1, in participants with PSP.
Timeline
- Start
- 2026-06-30
- Primary completion
- 2030-09-28
- Completion
- 2030-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AADvac1 | Vaccine | — | Subcutaneous |